14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MRNA vs ONC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs ONC. Trailing 12-month operating profitability (MRNA -80.8% vs ONC 17.8%) and valuation multiples (MRNA 23.0x vs ONC 36.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment38.8% of Rev ($980M)
90D Engineering Disclosures0 Published · mRNA Therapeutics
ONC Moat ProfileScale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $45.7B market capitalization and 17.8% operating margin.
OpEx & R&D Reinvestment71.6% of Rev ($4.73B)
90D Engineering Disclosures0 Published
Investor FAQ MRNA vs ONC Key Questions & Quantitative Answers
As of Nov 20, 2026, BeOne Medicines Ltd. (ONC) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas ONC carries 48.0/100 (HOLD) at $390.94 (36.2x Forward P/E, 17.8% operating margin). Technically, MRNA sits in a Neutral phase (RSI 41.5, CONSOLIDATION options structure) and ONC sits in a Neutral phase (RSI 50.0, UNCLASSIFIED options structure).
ONC leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with ONC at +33.8% YoY revenue growth and +212.5% YoY earnings growth on $6.61B TTM revenue (89.4% gross margin, 17.8% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $6.61B for ONC. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 71.6% of Rev ($4.73B) (0 disclosures) for ONC.
MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas ONC trades at 36.2x Forward P/E, 51.2x Trailing P/E, 0.71x PEG, and 6.9x EV/Revenue (20.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus ONC (18.4% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, ONC carries 45.8% implied volatility (23rd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 37% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.